167 related articles for article (PubMed ID: 24900625)
1. Design and Discovery of 2-Arylquinazolin-4-ones as Potent and Selective Inhibitors of Tankyrases.
Nathubhai A; Wood PJ; Lloyd MD; Thompson AS; Threadgill MD
ACS Med Chem Lett; 2013 Dec; 4(12):1173-7. PubMed ID: 24900625
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.
Nathubhai A; Haikarainen T; Hayward PC; Muñoz-Descalzo S; Thompson AS; Lloyd MD; Lehtiö L; Threadgill MD
Eur J Med Chem; 2016 Aug; 118():316-27. PubMed ID: 27163581
[TBL] [Abstract][Full Text] [Related]
3. Exploration of the nicotinamide-binding site of the tankyrases, identifying 3-arylisoquinolin-1-ones as potent and selective inhibitors in vitro.
Paine HA; Nathubhai A; Woon EC; Sunderland PT; Wood PJ; Mahon MF; Lloyd MD; Thompson AS; Haikarainen T; Narwal M; Lehtiö L; Threadgill MD
Bioorg Med Chem; 2015 Sep; 23(17):5891-908. PubMed ID: 26189030
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis and evaluation in vitro of arylnaphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases.
Kumpan K; Nathubhai A; Zhang C; Wood PJ; Lloyd MD; Thompson AS; Haikarainen T; Lehtiö L; Threadgill MD
Bioorg Med Chem; 2015 Jul; 23(13):3013-32. PubMed ID: 26026769
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.
Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C
J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
7. Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.
Haikarainen T; Narwal M; Joensuu P; Lehtiö L
ACS Med Chem Lett; 2014 Jan; 5(1):18-22. PubMed ID: 24900770
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of selective inhibition of human tankyrases.
Narwal M; Venkannagari H; Lehtiö L
J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
[TBL] [Abstract][Full Text] [Related]
9. Unravelling the Structural Mechanism of Action of 5-methyl-5-[4-(4-oxo-3H-quinazolin-2-yl)phenyl]imidazolidine-2,4-dione in Dual-Targeting Tankyrase 1 and 2: A Novel Avenue in Cancer Therapy.
Peters XQ; Agoni C; Soliman MES
Cell Biochem Biophys; 2022 Sep; 80(3):505-518. PubMed ID: 35637423
[TBL] [Abstract][Full Text] [Related]
10. Tankyrases as drug targets.
Lehtiö L; Chi NW; Krauss S
FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
[TBL] [Abstract][Full Text] [Related]
11. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
[TBL] [Abstract][Full Text] [Related]
12. 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.
Nkizinkiko Y; Desantis J; Koivunen J; Haikarainen T; Murthy S; Sancineto L; Massari S; Ianni F; Obaji E; Loza MI; Pihlajaniemi T; Brea J; Tabarrini O; Lehtiö L
Sci Rep; 2018 Jan; 8(1):1680. PubMed ID: 29374194
[TBL] [Abstract][Full Text] [Related]
13. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
[TBL] [Abstract][Full Text] [Related]
14. Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity.
Nathubhai A; Haikarainen T; Koivunen J; Murthy S; Koumanov F; Lloyd MD; Holman GD; Pihlajaniemi T; Tosh D; Lehtiö L; Threadgill MD
J Med Chem; 2017 Jan; 60(2):814-820. PubMed ID: 27983846
[TBL] [Abstract][Full Text] [Related]
15. para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.
Haikarainen T; Koivunen J; Narwal M; Venkannagari H; Obaji E; Joensuu P; Pihlajaniemi T; Lehtiö L
ChemMedChem; 2013 Dec; 8(12):1978-85. PubMed ID: 24130191
[TBL] [Abstract][Full Text] [Related]
16. Evidence for tankyrases as antineoplastic targets in lung cancer.
Busch AM; Johnson KC; Stan RV; Sanglikar A; Ahmed Y; Dmitrovsky E; Freemantle SJ
BMC Cancer; 2013 Apr; 13():211. PubMed ID: 23621985
[TBL] [Abstract][Full Text] [Related]
17.
Loganathan L; Muthusamy K; Jayaraj JM; Kajamaideen A; Balthasar JJ
J Biomol Struct Dyn; 2019 Sep; 37(14):3637-3648. PubMed ID: 30204055
[TBL] [Abstract][Full Text] [Related]
18. Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
Lakshmi TV; Bale S; Khurana A; Godugu C
Curr Drug Targets; 2017; 18(10):1214-1224. PubMed ID: 27425647
[TBL] [Abstract][Full Text] [Related]
19. Tankyrases maintain homeostasis of intestinal epithelium by preventing cell death.
Ye P; Chiang YJ; Qi Z; Li Y; Wang S; Liu Y; Li X; Chen YG
PLoS Genet; 2018 Sep; 14(9):e1007697. PubMed ID: 30260955
[TBL] [Abstract][Full Text] [Related]
20. The binding mechanism of a novel nicotinamide isostere inhibiting with TNKSs: a molecular dynamic simulation and binding free energy calculation.
Feng TT; Zhang YJ; Chen H; Fan S; Han JG
J Biomol Struct Dyn; 2016; 34(3):517-28. PubMed ID: 25933061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
